Revenue Up 2.5% Year-over-Year to RMB40,341 Million; Excluding COVID-19 Commercial Projects, Up 25.6% Net Profit Attributable to the Owners of the Company[1] Increased 9.0% to RMB9,607 Million; Diluted
SHANGHAI, March 18, 2024 /PRNewswire/ -- WuXi AppTec , a global company that provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical and life sciences industry, today announced its financial results for the year ending December 31, 2023 :Despite uncertainties in the external environment, revenue is expected to reach RMB 38.3 -40.5 billion in 2024, and maintain positive growth of 2.7-8.6% excluding COVID-19 commercial projects.
ii. In 2023, we added 1,255 new molecules to our D&M pipeline. By end of 2023, our D&M pipeline reached 3,201 molecules, including 61 commercial projects, 66 in phase III, 326 in phase II and 2,748 in phase I and pre-clinical stages, among which 20 commercial and phase III projects were added during the year.
ii. In 2023, the number of TIDES D&M customers increased 36% year-over-year to 140, and the number of TIDES molecules increased 41% year-over-year to 267.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Amundi MSCI EMU ESG CTB Net Zero Ambition UCITS ETF Dist: Net Asset Value(s)DJ Amundi MSCI EMU ESG CTB Net Zero Ambition UCITS ETF Dist: Net Asset Value(s) Amundi MSCI EMU ESG CTB Net Zero Ambition UCITS ETF Dist (MFDD LN) Amundi MSCI EMU ESG CTB Net Zero Ambition UCITS ETF
Weiterlesen »
Amundi MSCI Europe PAB Net Zero Ambition UCITS ETF Acc: Net Asset Value(s)DJ Amundi MSCI Europe PAB Net Zero Ambition UCITS ETF Acc: Net Asset Value(s) Amundi MSCI Europe PAB Net Zero Ambition UCITS ETF Acc (EABE LN) Amundi MSCI Europe PAB Net Zero Ambition UCITS ETF Acc:
Weiterlesen »
Amundi USD Corporate Bond PAB Net Zero Ambition - UCITS ETF Acc: Net Asset Value(s)DJ Amundi USD Corporate Bond PAB Net Zero Ambition - UCITS ETF Acc: Net Asset Value(s) Amundi USD Corporate Bond PAB Net Zero Ambition - UCITS ETF Acc (USIC LN) Amundi USD Corporate Bond PAB Net Zero
Weiterlesen »
Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billionCHICAGO, March 15, 2024 /PRNewswire/ -- Monoclonal Antibody (mABs) Therapeutics Market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion
Weiterlesen »
Siltronic Buy (Jefferies & Company Inc.) 12.03.2024 | AnalyseSiltronic Buy (Jefferies & Company Inc.) 12.03.2024 | Analyse | finanzen.net
Weiterlesen »
Suche nach Discount-Zertifikaten | finanzen.netÜbersicht über alle wichtigen und handelbaren Zertifikate - mit Zertifikate-Suche, Zertifikate-Vergleich und Analysen. Extra: Die beliebtesten Zertifikate.
Weiterlesen »